Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study-Reference-Cited by-同舟云学术

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

Published:2017-08-16 Issue:11 Volume:56 Page:1993-2003
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

McInnes Iain B¹,Mease Philip J²,Ritchlin Christopher T³,Rahman Proton⁴,Gottlieb Alice B⁵,Kirkham Bruce⁶,Kajekar Radhika⁷,Delicha Eumorphia-Maria⁸,Pricop Luminita⁷,Mpofu Shephard⁸

Affiliation:

1. Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK

2. Division of Rheumatology Clinical Research, Swedish Medical Centre and University of Washington, Seattle, WA

3. Allergy/Immunology and Rheumatology Division, University of Rochester, Rochester, NY, USA

4. Faculty of Medicine, Memorial University, St. John’s, NL, Canada

5. Department of Dermatology, New York Medical College, Valhalla, NY, USA

6. Rheumatology Department, Guy’s & St Thomas’ NHS Foundation Trust, London, UK

7. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

8. Novartis Pharma, Basel, Switzerland

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/56/11/1993/24245762/kex301.pdf

Reference26 articles.

1. Prevalence of joint disease in patients with psoriasis: implications for therapy;Zachariae;Am J Clin Dermatol,2003

2. Psoriatic arthritis: epidemiology, clinical features, course, and outcome;Gladman;Ann Rheum Dis,2005

3. Burden of disease: psoriasis and psoriatic arthritis;Boehncke;Am J Clin Dermatol,2013

4. Secukinumab in plaque psoriasis—results of two phase 3 trials;Langley;N Engl J Med,2014

5. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis;Ash;Ann Rheum Dis,2012

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis;Arthritis Research & Therapy;2024-02-15

2. Secukinumab after first-line tumor necrosis factor-alpha inhibitor therapy in psoriatic arthritis: A real-world retrospective cohort study;Archives of Rheumatology;2024-01-31

3. Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis;Pharmaceuticals;2023-12-21

4. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis;European Journal of Internal Medicine;2023-12

5. Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension;Seminars in Arthritis and Rheumatism;2023-12